[{"id":"5ab5758f-ded0-479b-83dd-b16b495d0f1a","acronym":"FASCINATE-N","url":"https://clinicaltrials.gov/study/NCT05582499","created_at":"2022-10-17T13:56:00.115Z","updated_at":"2025-02-25T12:29:07.250Z","phase":"Phase 2","brief_title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","source_id_and_acronym":"NCT05582499 - FASCINATE-N","lead_sponsor":"Fudan University","biomarkers":" HER-2 • PGR • CD8 • FOXC1","pipe":"","alterations":" ","tags":["HER-2 • PGR • CD8 • FOXC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 716","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-27"},{"id":"d794956d-7d72-4864-b172-3cc363bc86b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06649331","created_at":"2025-02-26T09:16:39.825Z","updated_at":"2025-02-26T09:16:39.825Z","phase":"Phase 2","brief_title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","source_id_and_acronym":"NCT06649331","lead_sponsor":"Fudan University","biomarkers":" HER-2 • NECTIN4 • TACSTD2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2 • NECTIN4 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • ruzaltatug rezetecan (SHR-A2009) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 10/21/2024","start_date":" 10/21/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-12-10"},{"id":"f5068016-59e0-4acd-94dd-b75bbe855ac9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04818333","created_at":"2021-03-26T14:52:26.950Z","updated_at":"2024-07-02T16:34:26.372Z","phase":"Phase 1/2","brief_title":"A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04818333","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 mutation • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 mutation • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 157","initiation":"Initiation: 04/23/2021","start_date":" 04/23/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-13"},{"id":"3389546b-7889-41d7-a623-1ac7e9ef8f61","acronym":"","url":"https://clinicaltrials.gov/study/NCT05924256","created_at":"2023-06-29T14:09:00.727Z","updated_at":"2024-07-02T16:35:14.639Z","phase":"Phase 2","brief_title":"A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing","source_id_and_acronym":"NCT05924256","lead_sponsor":"Fudan University","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 mutation • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-03-15"},{"id":"47481f7c-4d73-4ee0-9312-6b63c4d1442d","acronym":"BCTOP-L-M05","url":"https://clinicaltrials.gov/study/NCT05594095","created_at":"2022-10-26T13:56:12.698Z","updated_at":"2024-07-02T16:35:20.799Z","phase":"Phase 2","brief_title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","source_id_and_acronym":"NCT05594095 - BCTOP-L-M05","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-02-06"},{"id":"ad8ff218-f482-4c2e-97da-fbf04e789fb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015048","created_at":"2023-08-29T16:10:03.670Z","updated_at":"2024-07-02T16:35:21.190Z","phase":"Phase 1/2","brief_title":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.","source_id_and_acronym":"NCT06015048","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Recruiting","enrollment":" Enrollment 364","initiation":"Initiation: 08/11/2023","start_date":" 08/11/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 12/29/2026","study_completion_date":" 12/29/2026","last_update_posted":"2024-02-02"},{"id":"435158fa-5968-4e80-bf8f-2f21ac9fff3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05911958","created_at":"2023-06-22T20:09:27.571Z","updated_at":"2024-07-02T16:35:25.706Z","phase":"Phase 2","brief_title":"A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer","source_id_and_acronym":"NCT05911958","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 07/05/2023","start_date":" 07/05/2023","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2023-12-20"},{"id":"3021086a-786c-4af8-a4e0-81853c18a380","acronym":"","url":"https://clinicaltrials.gov/study/NCT05749588","created_at":"2023-03-01T15:02:09.008Z","updated_at":"2024-07-02T16:35:29.227Z","phase":"Phase 2","brief_title":"FUSCC Refractory TNBC Platform Study (FUTURE2.0)","source_id_and_acronym":"NCT05749588","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/30/2023","start_date":" 03/30/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-11-14"},{"id":"b195aa71-00ee-4ed5-a0ad-edf29d971b87","acronym":"","url":"https://clinicaltrials.gov/study/NCT05769010","created_at":"2023-03-15T14:02:15.990Z","updated_at":"2024-07-02T16:35:32.713Z","phase":"Phase 2","brief_title":"Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases","source_id_and_acronym":"NCT05769010","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/31/2023","start_date":" 03/31/2023","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-10-19"},{"id":"71e8ba1c-c547-49df-b8ba-11c83dde7a1b","acronym":"SHR-A1811-307","url":"https://clinicaltrials.gov/study/NCT06057610","created_at":"2023-09-28T15:10:54.069Z","updated_at":"2025-02-25T13:55:36.478Z","phase":"Phase 3","brief_title":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT06057610 - SHR-A1811-307","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 864","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2023-09-27"},{"id":"e9088b3f-0868-41a9-b517-cccbd53cad7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05845138","created_at":"2023-05-06T15:04:34.884Z","updated_at":"2024-07-02T16:35:41.287Z","phase":"Phase 1/2","brief_title":"A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.","source_id_and_acronym":"NCT05845138","lead_sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 07/25/2023","start_date":" 07/25/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-01"},{"id":"3b884a60-1aab-4641-b487-0cfd8270abc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04446260","created_at":"2021-01-18T21:23:47.759Z","updated_at":"2024-07-02T16:35:42.282Z","phase":"Phase 1","brief_title":"A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT04446260","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 mutation • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Recruiting","enrollment":" Enrollment 226","initiation":"Initiation: 09/03/2020","start_date":" 09/03/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-07-21"},{"id":"3341c515-8fd5-4854-8572-df35854a5230","acronym":"","url":"https://clinicaltrials.gov/study/NCT05814354","created_at":"2023-04-14T14:03:26.972Z","updated_at":"2024-07-02T16:35:42.463Z","phase":"Phase 3","brief_title":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial","source_id_and_acronym":"NCT05814354","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Recruiting","enrollment":" Enrollment 530","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2023-07-20"},{"id":"a1395b45-05a9-4fc5-8f4a-9958994ec2e1","acronym":"GALAXY","url":"https://clinicaltrials.gov/study/NCT05824325","created_at":"2023-04-21T15:04:38.742Z","updated_at":"2024-07-02T16:35:44.633Z","phase":"Phase 1/2","brief_title":"Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）","source_id_and_acronym":"NCT05824325 - GALAXY","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 04/10/2025","primary_completion_date":" 04/10/2025","study_txt":" Completion: 10/10/2026","study_completion_date":" 10/10/2026","last_update_posted":"2023-06-27"},{"id":"dd523315-933e-4b07-983a-f874fc81fa59","acronym":"","url":"https://clinicaltrials.gov/study/NCT05671822","created_at":"2023-01-05T14:58:24.565Z","updated_at":"2024-07-02T16:35:51.127Z","phase":"Phase 2","brief_title":"Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer","source_id_and_acronym":"NCT05671822","lead_sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • trastuzumab rezetecan (SHR-A1811) • retlirafusp alfa (SHR-1701)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2023-04-07"},{"id":"5d296ae8-3e34-4274-aa11-599071a50523","acronym":"","url":"https://clinicaltrials.gov/study/NCT05792410","created_at":"2023-03-31T15:02:42.573Z","updated_at":"2024-07-02T16:35:51.717Z","phase":"Phase 1/2","brief_title":"A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.","source_id_and_acronym":"NCT05792410","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • fulvestrant • letrozole • anastrozole • trastuzumab rezetecan (SHR-A1811) • AiRuiKang (dalpiciclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 02/27/2024","primary_completion_date":" 02/27/2024","study_txt":" Completion: 02/27/2025","study_completion_date":" 02/27/2025","last_update_posted":"2023-03-31"},{"id":"90a8d4bb-f8c6-4eb9-9a00-32e183f6c04e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05635487","created_at":"2022-12-02T15:56:35.557Z","updated_at":"2024-07-02T16:35:52.890Z","phase":"Phase 2","brief_title":"A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients","source_id_and_acronym":"NCT05635487","lead_sponsor":"Shengjing Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/28/2029","study_completion_date":" 02/28/2029","last_update_posted":"2023-03-21"},{"id":"60a3e324-4a65-41bc-a7ea-bb0bf8cd4ce8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05424835","created_at":"2022-06-22T00:55:26.244Z","updated_at":"2024-07-02T16:36:05.758Z","phase":"Phase 3","brief_title":"A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane","source_id_and_acronym":"NCT05424835","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)"],"overall_status":"Recruiting","enrollment":" Enrollment 269","initiation":"Initiation: 07/29/2022","start_date":" 07/29/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-08-10"},{"id":"0a173281-9947-4d4a-b39e-1060b81e2518","acronym":"","url":"https://clinicaltrials.gov/study/NCT05349409","created_at":"2022-04-27T12:54:29.401Z","updated_at":"2024-07-02T16:36:07.963Z","phase":"Phase 2","brief_title":"A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers","source_id_and_acronym":"NCT05349409","lead_sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 212","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2022-06-30"}]